IRVINE, Calif., Oct. 23, 2013 /PRNewswire/ -- A newly issued Sentinel Event Alert from the Joint Commission calls attention to the frequency of and patient and economic consequences from unintended retained foreign objects after surgery. Entitled "Preventing unintended retained foreign objects", Sentinel Event Alert Issue 51 was issued by the Joint Commission on October 17th and discusses, among other items, the physical harm to patients from retained items, the most common objects left behind, the associated costs from this error and recommendations and potential strategies for prevention.
Published for Joint Commission accredited organizations and interested health care professionals, Sentinel Event Alerts identify specific types of sentinel and adverse events and high risk conditions, describes their common underlying causes and recommends steps to reduce risk and prevent future occurrence. The Joint Commission recommends that accredited organizations consider information in an Alert when designing or redesigning processes and consider implementing relevant suggestions contained in the Alert or reasonable alternatives. The full copy of Sentinel Event Alert can be found at http://www.jointcommission.org/sea_issue_51/.
As discussed in Sentinel Event Alert 51, "Guidelines, processes and tools have become available to help team members develop risk-reduction strategies than can be adopted and followed organization-wide. These strategies include improved multi-stakeholder perioperative processes, enhanced team communication and the use of assistive technology."
"This action by the Joint Commission illustrates the growing awareness of and intolerance for preventable surgical errors and the specific attention being focused on one of the most common, retained surgical sponges," stated Brian E. Stewart<
SOURCE Patient Safety Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Answering the Call to Alarm Safety: Getting Ready for Joint Commissions National Patient Safety Goal
2. A*STARs SIMTech and NUS Faculty of Engineering Launch Joint Labs to Boost Manufacturing Productivity
3. Neusoft Medical Signed Transfer Agreement with Philips to Acquire 25% Equities in Philips-Neusoft Medical Systems Joint Venture
4. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
5. Biozoom Exercises Purchase Option Under Joint Venture Agreement With Spectroscopic Technology Developer, Opsolution
6. CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators
7. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
8. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
9. RNL BIO Co. Ltd. stellt IND-Antrag, um klinische Phase-II-Studie des RNL-JointStem gegen Arthrose in den Vereinigten Staaten einzuleiten
10. RNL BIO Co. Ltd. lämnar in IND-ansökan om att påbörja klinisk fas II-prövning av RNL-JointStem för artros i USA
11. RNL BIO Co. Ltd. Files IND To Commence Phase II Clinical Trial Of RNL-JointStem For Osteoarthritis In The United States